- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07938294
Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension (METH-FOCUS)
Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)
The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:
- Echocardiographic measurements of pulmonary hypertension
- Change in 6-minute walk distance (6MWD)
- Change in categorization of disease (World Health Organization Functional Class, WHO FC)
- Quality of life improvements
Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities:
- Physical exam
- Labs including drug screening
- Pulmonary function testing (PFT)
- Exercise testing (6MWD)
- Echocardiography
- Right heart catheterization (RHC)
- Questionnaires related to their disease
Participants will be in the study for about six months.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Samantha Ruimy, MS
- Numéro de téléphone: 503-494-0724
- E-mail: ruimy@ohsu.edu
Sauvegarde des contacts de l'étude
- Nom: Allyson Knapper, MD
- Numéro de téléphone: 503-494-5531
- E-mail: knapper@ohsu.edu
Lieux d'étude
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- The Queen's Medical Center
-
Contact:
- Gehan Devendra, MD
- Numéro de téléphone: 9168027603
- E-mail: devendra@hawaii.edu
-
Chercheur principal:
- Gehan Devendra, MD
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health & Science University
-
Contact:
- Allyson Knapper, MD
- Numéro de téléphone: 5034945531
- E-mail: knapper@ohsu.edu
-
Contact:
- Samantha Ruimy, MS
- Numéro de téléphone: 5034940724
- E-mail: ruimy@ohsu.edu
-
Chercheur principal:
- Jeffrey C Robinson, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years
- Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis
- Symptomatic PAH classified as WHO FC II or III
- Diagnosis of PAH within 12 months of screening and on stable doses of a ERA and PDE5i combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
- 6MWD ≥ 150 m completed at screening visit
- Females of childbearing potential must meet the following criteria: Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; Agree to ongoing pregnancy testing (either urine or serum) during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active with a male partner, use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment; Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
- Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy; Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
- Ability to adhere to study visit schedule and understand and comply with all protocol requirements
- Ability to understand and provide documented informed consent
Exclusion Criteria:
- Diagnosis of PH WHO Groups 2, 3, 4, or 5
- Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis- associated PAH, collagen vascular disease- associated PAH, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis
- Hgb at screening above gender-specific ULN, per local laboratory test
- Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
- Baseline systolic BP < 90 mmHg at screening
- Pregnant or breastfeeding women
- Any of the following clinical laboratory values at the Screening Visit: eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation), serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN, platelet count < 50,000/mm3 (< 50.0 × 109/L)
- Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent
- Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept
- History of pneumonectomy
- Pulmonary function test values of forced vital capacity < 60% predicted within 1 year prior to the Screening Visit
- Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
- Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
- Untreated more than mild obstructive sleep apnea
- History of known pericardial constriction
- History of restrictive cardiomyopathy
- History of atrial septostomy within 180 days prior to the Screening Visit
- Personal or family history of long QT syndrome or sudden cardiac death
- Left ventricular ejection fraction < 50% documented by a historical ECHO or cardiac MRI within the last 12 months prior to screening (if there is more than one assessment of LVEF, the value from the most recent measurement should be used in assessing eligibility)
- Coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the Screening Visit
- Cerebrovascular accident within 3 months prior to the Screening Visit
- Acutely decompensated left heart failure within 30 days prior to the Screening Visit, as per investigator assessment
- Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
- Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
- Active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sotatercept with addiction medicine services
|
Sotatercept given in coordination with addiction medicine services |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment response in methamphetamine-associated PAH
Délai: 24 weeks
|
The main hypothesis is that the addition of sotatercept to standard background therapy and addiction medicine services will improve treatment response in meth-APAH, as measured by the echocardiographic parameter TAPSE divided by RVSP (mm/mmHg). |
24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jeffrey C Robinson, MD, Oregon Health and Science University
Publications et liens utiles
Publications générales
- D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991 Sep 1;115(5):343-9. doi: 10.7326/0003-4819-115-5-343.
- Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grunig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6.
- L.J. Oppegard , J.C. Robinson , G. Devendra. Case Series: Marked Attenuation of Methamphetamine-associated Pulmonary Arterial Hypertension with Methamphetamine Cessation and Pharmacologic Therapy. American Journal of Respiratory and Critical Care Medicine 2024;209:A6117
- Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. doi: 10.1164/rccm.201705-0943OC.
- Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol. 1998 Apr;51(4):361-4. doi: 10.1016/s0895-4356(97)00289-8.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00028866
- 103326 (Autre subvention/numéro de financement: Merck Sharp & Dohme, LLC)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified data may be shared with qualified investigators upon request. Requests for access should include a brief description of the proposed research objectives, anticipated use of the data, and plans for data security and confidentiality. Data sharing will be considered for researchers with a legitimate scientific purpose, provided the proposed use is consistent with participant consent, applicable regulatory requirements, and institutional policies.
Délai de partage IPD
IPD and supporting information will be available from the date of results publication to ten years post-publication.
Critères d'accès au partage IPD
All requests will be reviewed by the Principal Investigator, who will evaluate whether: (1) the proposed use is appropriate and scientifically justified; (2) the requested data are necessary for the stated purpose; (3) the proposed use is consistent with participant consent and IRB requirements; and (4) adequate measures are in place to protect data confidentiality and security. Approved recipients may be required to execute a data use agreement prior to receiving study data.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .